A Phase 1 clinical trial testing the experimental therapy IDE034 in people with various types of cancer, including gynecological cancers, is expected to start…
Gynecological cancer
Dosing has begun in a Phase 3 clinical trial testing Enhertu (trastuzumab deruxtecan) as a maintenance treatment for certain people with ovarian cancer. The…
A new experimental therapy, DT2216, has begun testing in a clinical trial for people with hard-to-treat ovarian cancer, a significant step forward announced by…
The Ovarian Cancer Research Alliance (OCRA) launched a project to push lawmakers to enact legislation that will improve the lives of people affected by…
A committee of the World Health Organization (WHO) has approved an international nonproprietary name (INN) for Anixa Biosciences’ experimental cell therapy for ovarian cancer. The…
A combination of chemotherapy and immune-modulating therapies administered directly into the abdomen may help control ovarian cancer that has spread within the abdominal cavity, data…
Canada’s Drug Agency (CDA-AMC) has recommended that Canadian public drug plans cover the cost of the gynecological cancer therapy Elahere (mirvetuximab soravtansine) under…
Specific genetic changes in small populations of tumor cells can help to make ovarian cancer resistant to treatment, a new study by U.S. researchers revealed.
Nearly half of women with hard-to-treat endometrial cancer responded to the investigational therapy Rina-S (rinatabart sesutecan) in a Phase 2 clinical trial, according to new…
Corcept Therapeutics has submitted an application to the European Medicines Agency seeking approval of relacorilant for the treatment of platinum-resistant ovarian cancer. A similar…
